The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ALDX | -12.03% | -32.07% | -7.44% | -23% |
| S&P | +15.06% | +95.03% | +14.29% | +258% |
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
The company plans to conduct a public stock offering.
The company reported great clinical results for its lead pipeline candidate.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.06M | -1.1% |
| Market Cap | $229.40M | 16.6% |
| Market Cap / Employee | $28.68M | 0.0% |
| Employees | 8 | 0.0% |
| Net Income | -$9.77M | 42.0% |
| EBITDA | -$10.11M | 43.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $41.24M | 32.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.14M | 3.3% |
| Short Term Debt | $15.41M | -0.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -47.98% | -21.1% |
| Return On Invested Capital | -42.52% | 6.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$8.56M | 35.3% |
| Operating Free Cash Flow | -$8.56M | 35.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.26 | 3.49 | 4.83 | 3.62 | 108.55% |
| Price to Tangible Book Value | 3.26 | 3.49 | 4.83 | 3.62 | 108.55% |
| Enterprise Value to EBITDA | -16.41 | -12.80 | -26.03 | -16.19 | 120.15% |
| Return on Equity | -43.1% | -58.5% | -65.2% | -65.9% | 98.58% |
| Total Debt | $15.61M | $15.30M | $15.57M | $15.56M | -0.51% |
ALDX earnings call for the period ending June 30, 2022.
ALDX earnings call for the period ending March 31, 2022.
ALDX earnings call for the period ending December 31, 2021.
ALDX earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
